Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06304883 · ClinicalTrials.gov registry record · Phase 3
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
A Phase 3 study of Early Alzheimer's Disease, sponsored by Alzheon.
- Active
- Registry status
- Phase 3
- Development phase
- 163
- Enrollment target
- 20
- Study locations
NCT06304883: Active Phase 3 study of Early Alzheimer's Disease, sponsored by Alzheon.
NCT06304883 is a Phase 3 study of Early Alzheimer's Disease that is active but no longer recruiting, run by Alzheon. The registered enrollment target is 163 participants, below the 1,079-participant average among 7 other Early Alzheimer's Disease trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06304883, a Phase 3 study of Early Alzheimer's Disease, is active but no longer recruiting, sponsored by Alzheon.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 163 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.
Primary Outcome
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog 13), from baseline of Phase 3 core study (ALZ-801-AD301) to Week 52 and Week 104 of this long-term extension study (ALZ-801-AD351).
Conditions Studied
Interventions
- DRUG Experimental: ALZ-801
Study Locations (20)
Florida
- JEM Research Institute, Headlands Site - Atlantis
- K2 Medical Research, LLC - Maitland
- Mount Sinai Medical Center - Miami Beach
- Aqualane Clinical Research - Naples
- Charter Research - Orlando
- Progressive Medical Research - Port Orange
- ALZ Research and Treatment Center (A.R.T.C.) - Stuart
- ALZ Research and Treatment Center (A.R.T.C.) - Wellington
- Premiere Research Institute - West Palm Beach
California
- ATP Clinical Research - Costa Mesa
- Torrance Clinical Research Institute - Lomita
- Sutter Health - Sacramento
Arizona
- Xenoscience, Inc. - Phoenix
- Banner Sun Health Research Institute - Sun City
New York
- Neurological Associates of Albany - Albany
- NYU Alzheimer's Disease Research Center - New York
Georgia
- Columbus Memory Center - Columbus
Indiana
- Fort Wayne Neurological Center - Fort Wayne
Massachusetts
- Headlands Research Eastern MA - Plymouth
New Jersey
- Advanced Memory Research Center - Toms River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2027-01 |
| Phase | Phase 3 |
What the registry record for NCT06304883 still lists
NCT06304883 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, below the 1,079-participant average among 7 other Early Alzheimer's Disease trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Early Alzheimer's Disease appearing as the primary indexed condition, and to 1 intervention - of which Experimental: ALZ-801 is the first listed.
NCT06304883 names 20 study sites across 8 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06304883 about?
NCT06304883 is a clinical study titled "Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects". This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.
What is the current status of trial NCT06304883?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 163 participants. The study started on 2024-04-02. Estimated completion is 2027-01.
What conditions does trial NCT06304883 study?
This clinical trial studies the following conditions: Early Alzheimer's Disease.
What interventions are being tested in trial NCT06304883?
The interventions under investigation include: Experimental: ALZ-801 (DRUG).
Who is sponsoring clinical trial NCT06304883?
This trial is sponsored by Alzheon, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06304883 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
RECRUITING · Phase 3
-
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
COMPLETED · Phase 3
-
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI